This Study is Comparing Morning vs Random Scheduling of Standard of Care Pembrolizumab Checkpoint Inhibitor Immunotherapy Infusions in Patients With Metastatic Non-small Cell Lung Cancer
Clinical trial NCT06882174 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06882174
- Sponsor
- AHS Cancer Control Alberta
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-05-01
- Primary completion
- 2028-07-01
- Enrollment
- 58
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.